Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-33. (Canceled)

34.(Previously presented) A crystalline Form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl-]methoxy]benzyl]thiazolidine-2,4-dione potassium salt, having the formula:



, wherein the crystalline compound is characterized by having an x-ray powder diffraction pattern comprising one or more peaks expressed in degrees 2θ that are selected from the group consisting of 6.20, 9.34, 12.16, 12.48, 18.26, 18.80, 24.02, 24.46, 26.70, 27.02, 27.48, and 30.86 ± about 0.1.

35 – 57. (Cancelled)

58.(**Currently Amended**) A process for preparing the crystalline Form-I of ~~claim 35~~ **5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl-]methoxy]benzyl]thiazolidine-2,4-dione potassium salt, having the formula:**



, wherein the crystalline compound is characterized by having an x-ray powder diffraction pattern comprising one or more peaks expressed in degrees 2θ that are selected from the group consisting of 6.44, 7.42, 9.28, 10.76, 11.24, 16.16, 18.60, 25.06, 28.42, and 30.40 ± about 0.1,

the process comprising:

(i) dissolving 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione in an organic solvent, and heating to a temperature of about 60-75° C;

(ii) at a temperature of 40-55° C, adding potassium tertiary butoxide dissolved in an organic solvent **selected from methanol, a mixture of acetone and xylene, ethanol, isopropanol, ethyl acetate, diethyl ketone, and methyl isobutyl ketone**;

(iii) stirring the reaction mixture at a temperature of about 20-90° C;

(iv) cooling the reaction mixture to about room temperature; and

(v) recovering the crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt.

59.(Cancelled)

60.(Cancelled)

61.(Cancelled)

62. (Cancelled)

63.(**Currently Amended**) A process for preparing the crystalline Form-I of ~~claim 35~~ **5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl-]methoxy]benzyl]thiazolidine-2,4-dione potassium salt, having the formula:**



, wherein the crystalline compound is characterized by having an x-ray powder diffraction pattern comprising one or more peaks expressed in degrees 2θ that are selected from the group consisting of 6.44, 7.42, 9.28, 10.76, 11.24, 16.16, 18.60, 25.06, 28.42, and 30.40 ± about 0.1,

the process comprising:

(i) dissolving 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt in dimethylsulfoxide and heating to a temperature about 50-80° C;

(ii) storing the solution at room temperature for about 1-8 weeks; and

(iii) recovering the crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]- methoxy]benzyl]thiazolidine-2,4-dione potassium salt.

64.(New) A process for preparing the crystalline Form-I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl-]methoxy]benzyl]thiazolidine-2,4-dione potassium salt, having the formula:



, wherein the crystalline compound is characterized by having an x-ray powder diffraction pattern comprising one or more peaks expressed in degrees 2θ that are selected from the group consisting of 6.44, 7.42, 9.28, 10.76, 11.24, 16.16, 18.60, 25.06, 28.42, and 30.40 ± about 0.1,

the process comprising:

(i) dissolving 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione in an organic solvent selected from dimethylformamide, 1,4-dioxane, or a mixture of 1,4-dioxane and xylene, at room temperature;

(ii) at about room temperature, adding potassium tertiary butoxide dissolved in an organic solvent to the solution of step (i);

(iii) stirring the reaction mixture at about room temperature; and

(iv) recovering the crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]meth- oxy]benzyl]thiazolidine-2,4-dione potassium salt.

65. (New) A process for preparing the crystalline Form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl-]methoxy]benzyl]thiazolidine-2,4-dione potassium salt, having the formula:



, wherein the crystalline compound is characterized by having an x-ray powder diffraction pattern comprising one or more peaks expressed in degrees 2θ that are selected from the group consisting of 6.20, 9.34, 12.16, 12.48, 18.26, 18.80, 24.02, 24.46, 26.70, 27.02, 27.48, and 30.86 ± about 0.1, comprising:

(i) dissolving 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione in a mixture of acetonitrile and xylene;

(ii) cooling the solution of step (i) to about room temperature;

(iii) at about room temperature, adding potassium tertiary butoxide dissolved in methanol to the solution of step (i);

(vi) recovering the crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt.

66. (New) The crystalline Form of claim 34, wherein said compound comprises five or more of said x-ray powder diffraction peaks.

67. (New) The crystalline Form of claim 34, wherein said compound comprises all of said x-ray powder diffraction peaks.